Management of advanced gastric cancer

Timothy Price, Jeremy Shapiro, Eva Segelov, Christos Karapetis, N. Pavlakis, Eric Van Cutsem, Manish Shah, Yoon-Ku Yang, Niall Tebbutt

    Research output: Contribution to journalReview articlepeer-review

    68 Citations (Scopus)


    The management of advanced gastric cancer has only evolved a little over the last 15 years: platinum and fluoropyrimidine chemotherapy remains the backbone of therapy with ongoing debate as to the benefit of triplet therapy with either an anthracycline or taxane. Recently published trials of biological agents, in particular those targeting the Her2 receptor, have provided some signs of improvement. This article summarizes the relevant literature, discusses the role of these agents, as well as geographical variations in use, and provides recommendations regarding both 'standard chemotherapy' and the role of biological agents in advanced gastric cancer. Given the relative lack of progress for gastric cancer over the last 15 years, the focus for the next 5 years should be on an improved understanding of the molecular basis of gastric cancer, thus allowing rational integration of new molecular agents.

    Original languageEnglish
    Pages (from-to)199-209
    Number of pages11
    JournalExpert Review of Gastroenterolgy and Hepatology
    Issue number2
    Publication statusPublished - Apr 2012


    • chemotherapy
    • EGFR
    • gastric cancer
    • HER2
    • review
    • VEGF


    Dive into the research topics of 'Management of advanced gastric cancer'. Together they form a unique fingerprint.

    Cite this